Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest	$ (19,633)	$ (10,110)
Net loss attributable to noncontrolling interest	2,761	679
Net loss - as reported, attributable to PAVmed Inc.	(16,872)	(9,431)
Series B Convertible Preferred Stock dividends – earned	(68)	(75)
Net loss attributable to PAVmed Inc. common stockholders	$ (16,940)	$ (9,506)
Weighted average common shares outstanding, basic and diluted	86,336,427	73,954,126
Net loss - as reported, attributable to PAVmed Inc.	$ (0.20)	$ (0.13)
Net loss attributable to PAVmed Inc. common stockholders	$ (0.20)	$ (0.13)